Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant...

Descripción completa

Detalles Bibliográficos
Autores principales: Antepowicz, Agata, Habib, Omar, Kirsebom, Freja, Johansson, Cecilia, Gill, Deborah R., Hyde, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333317/
https://www.ncbi.nlm.nih.gov/pubmed/34344952
http://dx.doi.org/10.1038/s41598-021-95150-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333317/
https://www.ncbi.nlm.nih.gov/pubmed/34344952
http://dx.doi.org/10.1038/s41598-021-95150-z

Ejemplares similares